Clinical network segmentation testing starts with a care boundary
Clinical network segmentation testing verifies whether an agreed source can reach only the hospital systems and services it is supposed to reach, while essential clinical communications continue to work. The useful deliverable is a tested communication matrix with evidence, limitations and retest criteria. A diagram showing separate VLANs is an input to that work, not proof that the intended boundaries hold.
For a hospital, the objective includes both containment and availability. An administrative workstation should not acquire an unnecessary route into a medical-device management interface. At the same time, a corrective firewall change must not prevent an approved imaging workflow from reaching its required service. These are two sides of the same assessment: verify prohibited access and preserve the authorised clinical dependency.
This guide develops the validation matrix in detail. It complements our broader hospital segmentation testing overview and clinical network segmentation service. All scenarios below are hypothetical test designs. They require explicit hospital, clinical engineering and relevant supplier approval before use; they are not instructions to scan production medical devices indiscriminately.
Turn a high-level segmentation objective into measurable outcomes
Begin with the clinical service rather than a subnet list. Identify the workflow that needs protection, the systems supporting it and the people accountable for its availability. For an imaging service, the relevant chain may include modality acquisition, image storage, viewing, reporting and external support. For a laboratory, the dependency chain and tolerance for delay may be different. Record the specific service under discussion instead of treating every clinical network as interchangeable.
Write outcomes that the owners can approve. “The guest wireless network cannot initiate connections to the imaging management interface” is more precise than “medical devices are isolated.” “The approved acquisition path remains available after remediation” adds the positive requirement. Give each outcome an identifier and retain the owner’s rationale. That makes it possible to explain why a connection is needed rather than evaluating every reachable service as a defect.
Distinguish current requirements from proposed improvements. The assessor may recommend reducing a broad connection range, but the hospital must confirm the dependent workflow and supplier constraints before implementation. A finding should state the observed reachability, intended boundary and evidence of impact. It should not claim that an accessible port automatically establishes a patient-safety consequence that has not been evaluated.
| Outcome | Positive case | Negative case |
|---|---|---|
| Imaging acquisition | Approved modality test environment reaches its designated receiver | Unrelated administrative source cannot reach the restricted management service |
| Supplier maintenance | Approved support route reaches only named maintenance targets | The support identity cannot reach unrelated clinical zones |
| Clinical workstation access | Supported workstation completes its agreed read workflow | A designated untrusted source cannot initiate the same restricted connection |
| Management isolation | Approved engineering station reaches the authorised interface | Ordinary user network cannot access that interface |
Collect the information needed to design safe tests
Request current network diagrams, zone definitions, firewall policy references, asset ownership and the clinical dependency information available to the hospital. Record the confidence and age of each source. A diagram may describe the intended architecture while a rule export reflects a different current state. Preserve that distinction rather than silently combining them into a single authoritative map.
Identify device families, supported test methods and known sensitivity constraints through clinical engineering and suppliers. Do not assume a medical device behaves like an ordinary server because it uses Ethernet or has a familiar operating system. The agreed method may be configuration review, passive observation, a supplier-approved maintenance check or testing against an isolated representative system. Document the evidence each method can and cannot provide.
Collect relevant routing and security-control context as well as addressing. A logical zone name does not tell you whether traffic crosses an enforcing boundary. Equally, a route may exist while an access control prevents the operation of concern. The assessment needs enough context to distinguish network routing, permitted transport, application authentication and actual business capability without overstating any one layer.
Design the source-to-destination validation matrix
Give every case a defined source, destination, service, expected decision and method. Use an agreed test source that represents the network position being assessed. Record its addressing and relevant identity context at execution time. If network access depends on endpoint posture or a particular access method, include that in the case instead of assuming every device on a named network receives the same treatment.
Choose representative boundaries deliberately. Guest access, administrative endpoints, clinical workstations, medical-device zones, management networks and supplier entry points may need separate cases. Prioritise paths that cross materially different trust boundaries or support essential operations. A large number of repeated tests inside one zone does not compensate for missing the external support route that reaches several zones.
Avoid a matrix that labels every cell simply “allow” or “deny” without defining the operation. An allowed transport connection may still require application authentication, and an application may use several dependent services. State which layer the test verifies. If a case checks only transport reachability, its conclusion should remain transport reachability; do not describe it as successful access to clinical records.
| Matrix field | Required detail |
|---|---|
| Case identifier | Stable reference linked to the business outcome |
| Source | Approved test host, zone and relevant access context |
| Destination | Named system or representative approved endpoint |
| Service | Specific protocol or operation within the agreed method |
| Expected result | Permitted dependency or prohibited path |
| Safety limit | Rate, time window, stop condition and excluded actions |
| Evidence | Configuration reference and observed result with time |
| Disposition | Pass, fail, inconclusive or not tested, with reason |
Agree a safety envelope before any active validation
Establish an independent stop authority who can halt testing without waiting for a commercial or technical debate. Agree the communication channel, the people monitoring clinical services and the event that triggers suspension. These arrangements should be usable during the actual test window. A telephone number in a document is insufficient if nobody has confirmed availability or the person cannot assess the affected service.
Define the permitted traffic and prohibited techniques. The hospital may approve a narrowly bounded connection check while excluding vulnerability scanning, malformed input, authentication guessing or exploitation on a device. Record these distinctions in the rules of engagement. A general authorisation to perform a hospital pentest should not be interpreted as permission for every technique against every clinical asset.
Plan evidence collection and rollback together. Know which configuration changes, if any, are approved, who can reverse them and how clinical owners will verify recovery. In many assessments no production change is needed during testing. Where a validation depends on a planned change, treat it as a separate controlled activity with its own acceptance checks. Do not turn the assessment into an unannounced redesign of the clinical network.
Select the least disruptive method that answers the question
Use configuration review to understand intended enforcement and identify candidate gaps. Use authorised passive observations where they can clarify real dependencies. Use isolated or representative environments when active techniques would be inappropriate for the live system. Reserve production validation for specific questions that cannot be answered adequately otherwise, with the method and limits agreed by the relevant owners.
Each method has a different evidential limit. A firewall rule review can show an overly broad allowance but may not establish whether a destination service is currently listening. A connection check can demonstrate reachability without demonstrating application access. A lab test can validate device behaviour under the lab conditions but may not reproduce all production dependencies. The report should preserve these limits rather than presenting every method as equivalent.
The planning and technique-selection principles in NIST SP 800-115 provide a useful general assessment reference. It is not a hospital-specific permission to test medical devices or a substitute for manufacturer constraints. Use it to structure the engagement, then apply the hospital’s clinical and operational requirements to the individual cases.
Validate necessary traffic as carefully as prohibited traffic
Ask application and clinical owners to identify the essential dependencies for each sampled workflow. A network team may know the firewall rules but not the complete clinical operation. Conversely, a supplier may provide a broad connectivity document that contains optional or legacy services. Resolve these differences before changing a rule. The objective is the smallest justified communication set that supports the agreed operation, not the smallest rule count.
Create positive tests for the critical dependencies affected by a recommendation. These may be supervised functional checks rather than penetration-test actions. Record who performed them, what synthetic or approved workflow was used and what result was expected. Do not copy patient information into the assessment solely to demonstrate a route that can be verified with an approved test object or service-owner observation.
Where the dependency remains uncertain, raise a discovery or validation action rather than proposing immediate removal. A broad rule can be a genuine concern while still requiring careful remediation. The report should help the hospital move from uncertainty to a safe decision: identify the owner, collect the missing evidence, narrow the proposed change and define the verification window.
Include the supplier route in the boundary model
Remote maintenance may enter through a different route from ordinary hospital users. Identify the approved entry point, authentication arrangement, session controls and destination restrictions. Confirm which organisation operates each component and who can approve the test. A hospital contract with a supplier does not necessarily authorise testing the supplier’s unrelated infrastructure or a shared service used by other customers.
Define a representative maintenance case and an out-of-scope destination case. The first verifies the authorised route to the agreed target; the second checks that the same approved support context does not reach an unrelated zone where it should have no access. Use designated accounts and harmless operations. Avoid collecting supplier credentials or attempting to expand a real support session beyond the agreed boundaries.
Also examine lifecycle evidence: how support access is enabled, reviewed and removed, and how sessions are attributable. These are distinct from segmentation reachability, but they explain whether the route remains controlled over time. Link any unresolved ownership or offboarding issue to the technical finding rather than assuming a firewall correction alone addresses the entire supplier-access risk.
Capture enough evidence to reproduce the conclusion
For each case, record the UTC time, source context, destination, agreed operation and observed result. Preserve the relevant control reference or rule identifier where available. Capture only the evidence necessary to support the conclusion. Sensitive network details belong in the restricted technical pack, while the executive report can explain the affected service and consequence without publishing the complete architecture.
Distinguish a timeout from a demonstrated policy denial. A destination may be unavailable, an intermediate service may be failing or the test may have used the wrong context. If the evidence cannot determine why the operation failed, label the result inconclusive and identify the next check. Counting every failed connection as successful segmentation creates misleading assurance and can hide broken legitimate dependencies.
Correlate observations with the network or service owner where possible. The evidence should show whether the relevant enforcement point observed the case and how it treated it. If logs are unavailable, document that limitation. Do not substitute a confident narrative for missing records. A transparent inconclusive case is more actionable than a pass that cannot be explained or repeated.
Write a finding that separates reachability from impact
Consider a hypothetical case in which an approved administrative test source can establish a connection to a restricted imaging-management service. The requirement says that only the engineering management zone should reach it. The supported finding is an unintended network path to a management service. Whether that path enables privileged operations, data access or disruption requires additional evidence and separate authorisation; the report must not invent those outcomes.
Describe the affected boundary, observed operation, relevant control and business context. Explain why unnecessary exposure increases the options available after compromise of the source zone. If application authentication still applies, say so. If exploitation was excluded for safety, say so. These qualifications do not weaken the finding; they make the conclusion precise enough for the hospital to prioritise and correct it.
Recommend an owner-led change that addresses the path while validating the approved engineering workflow. Include the dependencies and uncertainty that must be resolved first. A useful remediation ticket names the rule or control, intended access set, change approver and retest case. “Improve segmentation” is too broad to be a closure condition.
Explain the sample and the untested boundaries
Publish a coverage summary that distinguishes configuration review, passive analysis, lab validation and live checks. Identify the zones and service families represented in each category. If a device family could not be tested safely, state that fact and describe the alternative evidence used. Do not turn a representative sample into a claim that every endpoint and every possible route was examined.
Explain why the selected cases matter. A sensible sample might cover each materially different enforcement path, important clinical dependency and supplier entry point. The rationale should reflect the hospital’s architecture rather than an arbitrary target count. Record known constraints such as unavailable maintenance windows or missing supplier confirmation, together with the follow-up action needed to close the evidence gap.
Track changes between collection and reporting. If the hospital modifies a relevant rule during the engagement, preserve the earlier observation and identify the later state separately. Otherwise a reviewer may struggle to reproduce a finding because the environment has already changed. A dated evidence chain allows the report to remain useful without pretending that network configuration is static.
Define retest acceptance before implementing the correction
A retest should repeat the original unwanted-path case from the same relevant source context, then verify the positive dependency that the correction must preserve. Confirm that the change is deployed at the intended enforcement point and that the case is not simply failing because the target is offline. Record the new configuration reference and observation time alongside the original finding.
Test neighbouring cases where the correction affects a shared rule or service. A narrowly described finding may lead to a change with broader consequences. The network and clinical owners should identify the legitimate workflows that require a post-change check. This is particularly important when consolidating legacy rules or moving a device family into a different zone.
Close the finding only when the agreed acceptance criteria are met. If the hospital retains a path for operational reasons, record the authorised risk decision, compensating controls and review date separately. If verification is deferred, leave the status clear. A change ticket marked complete is evidence of an administrative action; it is not automatically evidence that the segmentation boundary now behaves as intended.
Account for maintenance, failover and temporary exceptions
Ask whether the boundary changes during maintenance, failover or supplier intervention. A normal-state test may miss a temporary rule introduced during an outage and never removed. Identify these operating modes through interviews and change records, then decide which can be reviewed through configuration evidence and which need a separately approved rehearsal. Do not trigger a clinical failover just to expand test coverage.
Record the owner and expiry decision for each temporary exception relevant to the assessment. The evidence should explain what opens the route, how long it is needed, who confirms closure and how the hospital detects an exception that outlives its purpose. Where automated expiry is part of the design, verify the configuration and an appropriate controlled example rather than relying on the feature name.
Treat disaster-recovery and standby environments as explicit scope decisions. They may use different routing, identities or management arrangements from the primary environment. If they are excluded, the report should not imply that primary-site segmentation results cover them. If included, define the representative checks and operational constraints with the recovery owner. This keeps the assurance statement aligned with the actual environments reviewed.
Specify the matrix and evidence in your request for proposal
Ask prospective testers how they will identify clinical dependencies, select safe methods and handle uncertainty. Request a sample validation matrix and an example of a finding that distinguishes transport reachability from application impact. Confirm the role of clinical engineering, the independent stop authority and the expected supplier participation. These questions expose the practical differences between a hospital assessment and a generic network scan.
Define deliverables that your team can operate: a scoped communication matrix, evidence references, findings with owners, a coverage-and-limitations statement and retest acceptance criteria. Agree the secure format for detailed architecture and observations. The executive output should explain which clinical services have unnecessary exposure and what decisions are needed, while the technical output supports controlled remediation.
Do not select a proposal only by the number of IP addresses or days. Preparation quality, clinical coordination and the suitability of the method affect how much useful evidence the engagement can produce. A smaller, well justified set of safely validated boundaries can be more valuable than a large list of uncertain scanner observations. Ask what decisions the hospital will be able to make when the work is finished.
Prepare for a useful hospital segmentation engagement
Prepare a high-level service map, known supplier routes, relevant device families, current zone definitions and the people responsible for clinical availability. Identify the boundaries you most need to verify and the restrictions that apply. You do not need to send detailed patient-system diagrams or credentials through an initial enquiry form. Start with the objectives and agree secure evidence exchange before sharing sensitive material.
Our hospital pentest scoping tool helps outline the environment and testing constraints. You can also discuss clinical segmentation validation with Atlant Security. The engagement should produce a clear answer to three questions: which boundaries were verified, which necessary workflows were preserved, and what evidence remains outstanding. For the broader service, see hospital penetration testing.
Reviewed 25 October 2026. This is an assessment design guide, not a medical-device operating procedure or a declaration of regulatory compliance. Apply the hospital’s current authorisations, supplier constraints and change-control arrangements to every test case.
Published by Atlant Security. Sources, editorial policy and corrections.
